Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Janus Henderson Group PLC

Janus Henderson Group PLC raised its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 7.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,018 shares of the medical research company’s stock after acquiring an additional 3,268 shares during the quarter. Janus Henderson Group PLC owned 0.09% of Charles River Laboratories International worth $9,064,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the company. Tortoise Investment Management LLC grew its holdings in Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 57 shares in the last quarter. Wolff Wiese Magana LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter valued at about $32,000. Assetmark Inc. increased its position in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares during the last quarter. Whittier Trust Co. of Nevada Inc. lifted its stake in shares of Charles River Laboratories International by 219.3% in the second quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company’s stock worth $58,000 after acquiring an additional 193 shares in the last quarter. Finally, Covestor Ltd boosted its holdings in Charles River Laboratories International by 40.9% in the third quarter. Covestor Ltd now owns 327 shares of the medical research company’s stock valued at $65,000 after purchasing an additional 95 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Insiders Place Their Bets

In other news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Redburn Atlantic assumed coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price on the stock. CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a report on Monday, November 18th. Robert W. Baird decreased their price objective on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. UBS Group upped their target price on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, Evercore ISI lifted their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and a consensus price target of $214.38.

Charles River Laboratories International Stock Up 0.1 %

Charles River Laboratories International stock opened at $191.81 on Monday. The firm has a market capitalization of $9.81 billion, a P/E ratio of 24.01, a P/E/G ratio of 5.15 and a beta of 1.38. The company has a 50-day simple moving average of $194.10 and a 200-day simple moving average of $203.67. Charles River Laboratories International, Inc. has a one year low of $176.48 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. Charles River Laboratories International’s revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.72 earnings per share. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).